Cryo Cell International Inc.

CCEL

NYSE; healthcare; SIC 8090, Services-Misc Health & Allied Services, NEC; CIK 0000862692

C/D

on the C/D boundary of 370 graded peers in healthcare

rank 215 of 370; percentile 58.0; sampling error 2.5 points; lower is stronger




C/D, the tortoise



Scoreboard

Profitability	B/C percentile 39.1
Solvency	D percentile 68.1
Growth and financing	C percentile 44.9
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $61.7M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered
Inputs computable	11 of 14
Graded from	filings received through Feb 27, 2026 235 days before the rescan; latest periodic filing 10-Q received Oct 9, 2026
Last close	$4.15 2026-10-14; market equity $33.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

Cryo-Cell International, Inc. (the "Company" or "Cryo-Cell") is a Delaware corporation that was incorporated in 1989. The Company is organized in three reportable segments; 1.) cellular processing and cryogenic storage for family use, with a current focus on the collection and preservation of umbilical cord blood and tissue stem cells, 2.) the manufacture of PrepaCyte® CB Processing System ("PrepaCyte CB") units, the processing technology used to process umbilical cord blood stem cells, and 3.) cellular processing and cryogenic storage of umbilical cord blood stem cells for public use.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 39.1						
Gross profitability	39.2%	32.3%		34.3	371	2025-11-30
Return on invested capital	not computable	9.3%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(12.5%)	(6.6%)	34.9	812	2025-11-30
Gross margin stability, five years	2.8 pts	2.8 pts	48.1	242	2025-11-30
Solvency, sleeve percentile 68.1					
Twelve-month failure probability	0.57%	0.06%	85.8	247	2026-08-31
Altman Z double-prime	(3.07)	(0.30)	49.3	757	2025-11-30
Net debt to EBITDA	5.47x	1.82x	85.1	75	2025-11-30
Interest coverage	0.23x	(4.51x)	27.5	81	2025-11-30
Current ratio	0.59x	2.96x	92.8	840	2025-11-30
Growth and financing, sleeve percentile 44.9					
Revenue growth, three-year compound	1.3%	10.1%	69.0	414	2025-11-30
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(1.7%)	2.1%	54.8	705	2025-11-30
Net share issuance, one year	(0.3%)	2.5%	10.7	634	2026-02-28

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
210	Inogen Inc. (INGN)	56.6	C	fortress balance sheet
211	Cooper Companies, Inc. (COO)	56.9	C	
212	Aquestive Therapeutics, Inc. (AQST)	57.2	C	
213	Tango Therapeutics, Inc. (TNGX)	57.5	C	dilution
214	Rocket Pharmaceuticals, Inc. (RCKT)	57.7	C/D	degenerate inputs
215	Cryo Cell International Inc. (CCEL)	58.0	C/D	
216	Prestige Consumer Healthcare Inc. (PBH)	58.3	C/D	
217	Becton Dickinson & Co. (BDX)	58.5	C/D	
218	Option Care Health, Inc. (OPCH)	58.8	C/D	
219	Perspective Therapeutics, Inc. (CATX)	59.1	C/D	dilution, fortress balance sheet
220	electroCore, Inc. (ECOR)	59.3	C/D	

What the price implies

at the 2026-10-14 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(9.5%)	8.0%	40
Distance from 52-week high	0.0%	(31.9%)	98
EBIT to enterprise value	1.1%	(1.6%)	58
Free cash flow yield	14.0%	(1.0%)	94
Book value to price	(0.44)	0.28	4
Sales to price	0.84	0.31	78
Composite equity issuance, five years	not computable	20.3%	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	(0.31)	(0.13)	40

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-11-30	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$1.4M
Operating cash flow, four quarters	$4.9M
Months of runway	not finite
Days since last periodic filing	11 (10-Q received Oct 9, 2026)
Median daily dollar volume, 63 sessions	$39,848

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$31.6M	2025-11-30	2026-02-27	10-K	26-083096
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$7.4M	2025-11-30	2026-02-27	10-K	26-083096
3	assets	us-gaap:Assets	$61.7M	2025-11-30	2026-02-27	10-K	26-083096
4	operating income	us-gaap:OperatingIncomeLoss	$482,394	2025-11-30	2026-02-27	10-K	26-083096
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$2.3M	2025-11-30	2026-02-27	10-K	26-083096
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$92,232	2025-11-30	2026-02-27	10-K	26-083096
7	total debt	us-gaap:LongTermDebt	$8.4M	2025-11-30	2026-02-27	10-K	26-083096
8	book equity	us-gaap:StockholdersEquity	-$18.6M	2025-11-30	2026-02-27	10-K	26-083096
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$319,031	2025-11-30	2026-02-27	10-K	26-083096
10	total debt	us-gaap:LongTermDebt	$8.5M	2024-11-30	2026-02-27	10-K	26-083096
11	book equity	us-gaap:StockholdersEquity	-$13.2M	2024-11-30	2026-02-27	10-K	26-083096
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$560,960	2024-11-30	2026-02-27	10-K	26-083096
13	net income	us-gaap:NetIncomeLoss	-$2.4M	2025-11-30	2026-02-27	10-K	26-083096
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$5.5M	2025-11-30	2026-02-27	10-K	26-083096
15	assets	us-gaap:Assets	$64.7M	2024-11-30	2026-02-27	10-K	26-083096
16	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$32.0M	2024-11-30	2026-02-27	10-K	26-083096
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$7.9M	2024-11-30	2026-02-27	10-K	26-083096
18	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$31.3M	2023-11-30	2025-02-28	10-K	25-030138
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$8.4M	2023-11-30	2025-02-28	10-K	25-030138
20	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$30.3M	2022-11-30	2024-02-28	10-K	24-022275
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$8.8M	2022-11-30	2024-02-28	10-K	24-022275
22	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$28.9M	2021-11-30	2023-02-28	10-K	23-005220
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$9.0M	2021-11-30	2023-02-28	10-K	23-005220
24	current assets	us-gaap:AssetsCurrent	$11.8M	2025-11-30	2026-02-27	10-K	26-083096
25	current liabilities	us-gaap:LiabilitiesCurrent	$19.8M	2025-11-30	2026-02-27	10-K	26-083096
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$38.4M	2025-11-30	2026-02-27	10-K	26-083096
27	liabilities	us-gaap:Liabilities	$80.3M	2025-11-30	2026-02-27	10-K	26-083096
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$985,242	2025-11-30	2026-02-27	10-K	26-083096
29	interest expense	us-gaap:InterestExpense	$2.1M	2025-11-30	2026-02-27	10-K	26-083096
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$230,475	2025-11-30	2026-02-27	10-K	26-083096

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$6.0M	2024-11-30	2026-02-27	10-K	26-083096
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.4M	2024-11-30	2026-02-27	10-K	26-083096
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$8.9M	2023-11-30	2025-02-28	10-K	25-030138
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6.8M	2023-11-30	2025-02-28	10-K	25-030138
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$8.6M	2022-11-30	2024-02-28	10-K	24-022275
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$12.2M	2022-11-30	2024-02-28	10-K	24-022275
37	current assets	us-gaap:AssetsCurrent	$12.6M	2024-11-30	2026-02-27	10-K	26-083096
38	current liabilities	us-gaap:LiabilitiesCurrent	$21.6M	2024-11-30	2026-02-27	10-K	26-083096
39	assets	us-gaap:Assets	$61.2M	2023-11-30	2025-02-28	10-K	25-030138
40	assets	us-gaap:Assets	$64.9M	2022-11-30	2024-02-28	10-K	24-022275
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,055,150	2026-02-28	2026-02-27	10-K	26-083096
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,082,159	2025-02-28	2025-02-28	10-K	25-030138

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.